艾昆纬-全球肿瘤学趋势2025(英)

MAY2 0 2 5Adopting New Therapies as Modalities Shift and Expenditures RiseGlobal Oncology Trends 2025As a leading cause of premature death globally, cancer remains an important area for continued investment in screening and early diagnosis, access to care, and novel treatment modalities with improved clinical benefits. As a result, the innovation ecosystem that discovers, develops, and delivers breakthrough therapies continues to operate near peak levels and treatment in developed countries is shifting toward newer modalities. However, these shifts may further exacerbate disparities in access to cancer care in low- and middle-income countries and across demographic groups.Our research profiles the current state of research and development in oncology, including key mechanisms, targets, and cancer types being investigated as well as pointing to some novel areas which are only just emerging. We also look at metrics of clinical development productivity.As more novel cancer medicines are launched, patient access and use of those drugs vary widely around the world. Trends in the use of novel mechanisms in specific cancer types are reported here and intended to provide an evidence base that encourages stakeholder discussion.Finally, the costs associated with treating more patients for longer and with more advanced therapies is bringing stress to healthcare budgets, even as the broader adoption of biosimilars provides some relief and will play an important role in the years to come. How these spending dynamics will play out over the next five years globally is also examined in this report. This study was produced independently by the IQVIA Institute for Human Data Science as a public service, without industry or government funding. The contributions to this report of Srinidhi BC, Saksham Bhardwaj, Tanya Bhardwaj, Michael Brave, Jin Chen, Bryce Davies, Julia Kern, Raji Nair, Bhagyashree Sitaram Nawar, Urvashi Porwal, Carolina Ricarte, and many others at IQVIA are gratefully acknowledged. Find Out MoreIf you wish to receive future reports from the IQVIA Institute for Human Data Science or join our mailing list, visit iqviainstitute.org. MURRAY AITKENExecutive Director IQVIA Institute for Human Data ScienceIntroduction©2025 IQVIA and its affiliates. All reproduction rights, quotations, broadcasting, publications reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without express written consent of IQVIA and the IQVIA Institute.Global Oncology Trends 2025: Adopting New Therapies as Modalities Shift and Expenditures RiseREFERENCING THIS REPORTPlease use this format when referencing content from this report:Source: IQVIA Institute for Human Data Science. Global Oncology Trends 2025: Adopting New Therapies as Modalities Shift and Expenditures Rise. May 2025. Available from www.iqviainstitute.orgTable of C

立即下载
综合
2025-06-03
83页
3.4M
收藏
分享

艾昆纬-全球肿瘤学趋势2025(英),点击即可下载。报告格式为PDF,大小3.4M,页数83页,欢迎下载。

本报告共83页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共83页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
表5-1 近十年全球药企并购Top10
综合
2025-06-03
来源:2025年从引进到引领:中国创新药交易十年全景透视报告
查看原文
图5-4 近两年本土biotech被海外并购概览
综合
2025-06-03
来源:2025年从引进到引领:中国创新药交易十年全景透视报告
查看原文
图5-3 近10年TOP MNC并购数量及金额统计(亿美元)
综合
2025-06-03
来源:2025年从引进到引领:中国创新药交易十年全景透视报告
查看原文
图5-2 主要国家药企并购数量及总金额统计,2015-2024年(亿美元)
综合
2025-06-03
来源:2025年从引进到引领:中国创新药交易十年全景透视报告
查看原文
图5-1 全球药企并购数量及金额统计,2015-2024(亿美元)
综合
2025-06-03
来源:2025年从引进到引领:中国创新药交易十年全景透视报告
查看原文
表4-3 近十年中国License-out交易TOP10
综合
2025-06-03
来源:2025年从引进到引领:中国创新药交易十年全景透视报告
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起